{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:11:28Z","timestamp":1793293888251,"version":"4.5.0"},"reference-count":36,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>The optimal treatment strategy for anti-aminoacyl-tRNA synthetase antibody\u2013positive polymyositis\/dermatomyositis-associated interstitial lung disease (anti-ARS-PM\/DM-ILD) is yet to be established. We aimed to evaluate the efficacy of glucocorticoids and calcineurin inhibitors (CNI) in patients with ARS-PM\/DM-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Progression-free survival (PFS) and overall survival rates were retrospectively evaluated in 32 consecutive patients with ARS-PM\/DM-ILD. Disease progression was defined as deterioration in PM\/DM-ILD (including recurrence). Predictive factors associated with PFS were analyzed by Cox hazards analysis. The efficacy of first-line prednisolone (PSL) plus CNI therapy was compared with that of PSL monotherapy using propensity score\u2013matched analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Overall, 20 (62.5%) and 12 (37.5%) patients received first-line therapy with PSL + CNI and PSL, respectively. The 2-year PFS and 5-year survival rates in the overall cohort were 68.8% and 96.9%, respectively. On multivariate analysis, arterial oxygen pressure (HR 0.86) and PSL monotherapy (vs PSL + CNI; HR 7.29) showed an independent association with PFS. Baseline characteristics of propensity score-matched PSL + CNI and PSL groups were similar. The 2-year PFS rate was significantly higher in the matched PSL + CNI group than in the matched PSL group. All patients who experienced disease progression during first-line therapy were subsequently treated with second-line therapies. The 5-year survival rates of both the matched PSL + CNI and PSL groups were favorable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Propensity score\u2013matched analysis demonstrated that first-line PSL + CNI therapy for patients with ARS-PM\/DM-ILD significantly improved the PFS compared with PSL monotherapy, although there was no significant difference regarding longterm survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.180778","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T12:17:19Z","timestamp":1547554639000},"page":"509-517","source":"Crossref","is-referenced-by-count":41,"title":["Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody\u2013positive Polymyositis\/dermatomyositis\u2013associated Interstitial Lung Disease: A Propensity Score\u2013matched Analysis"],"prefix":"10.3899","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-1543","authenticated-orcid":false,"given":"Hironao","family":"Hozumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-1781","authenticated-orcid":false,"given":"Tomoyuki","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Karayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneyo","family":"Mimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2019,1,15]]},"reference":[{"key":"2019050109251922000_46.5.509.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"2019050109251922000_46.5.509.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807"},{"key":"2019050109251922000_46.5.509.3","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120621"},{"key":"2019050109251922000_46.5.509.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.10794"},{"key":"2019050109251922000_46.5.509.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2007.02.017"},{"key":"2019050109251922000_46.5.509.6","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00038806"},{"key":"2019050109251922000_46.5.509.7","first-page":"58","article-title":"Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis","volume":"32","author":"Fujisawa","year":"2005","journal-title":"J Rheumatol"},{"key":"2019050109251922000_46.5.509.8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098824"},{"key":"2019050109251922000_46.5.509.9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.resinv.2016.09.006","article-title":"Predictive factors for long-term outcome in polymyositis\/dermatomyositis-associated interstitial lung diseases","volume":"55","author":"Fujisawa","year":"2017","journal-title":"Respir Investig"},{"key":"2019050109251922000_46.5.509.10","doi-asserted-by":"publisher","DOI":"10.1080\/08916930500124023"},{"key":"2019050109251922000_46.5.509.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu166"},{"key":"2019050109251922000_46.5.509.12","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12451"},{"key":"2019050109251922000_46.5.509.13","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316651748"},{"key":"2019050109251922000_46.5.509.14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir Med"},{"key":"2019050109251922000_46.5.509.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep375"},{"key":"2019050109251922000_46.5.509.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq149"},{"key":"2019050109251922000_46.5.509.17","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","article-title":"Initial predictors of poor survival in myositis-associated interstitial lung disease: A multicentre cohort of 497 patients","volume":"57","author":"Sato","year":"2018","journal-title":"Rheumatology"},{"key":"2019050109251922000_46.5.509.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.21023"},{"key":"2019050109251922000_46.5.509.19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.amjms.2017.07.013","article-title":"Clinical heterogeneity of interstitial lung disease in polymyositis and dermatomyositis patients with or without specific autoantibodies","volume":"355","author":"Chen","year":"2018","journal-title":"Am J Med Sci"},{"key":"2019050109251922000_46.5.509.20","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0246-6"},{"key":"2019050109251922000_46.5.509.21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120313"},{"key":"2019050109251922000_46.5.509.22","doi-asserted-by":"publisher","DOI":"10.1080\/08916930600622884"},{"key":"2019050109251922000_46.5.509.23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060442"},{"key":"2019050109251922000_46.5.509.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201800"},{"key":"2019050109251922000_46.5.509.25","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"2019050109251922000_46.5.509.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2019050109251922000_46.5.509.27","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.2.ats01"},{"key":"2019050109251922000_46.5.509.28","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.ats3-00"},{"key":"2019050109251922000_46.5.509.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.22506"},{"key":"2019050109251922000_46.5.509.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.02.015"},{"key":"2019050109251922000_46.5.509.31","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20212"},{"key":"2019050109251922000_46.5.509.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.21240"},{"key":"2019050109251922000_46.5.509.33","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121026"},{"key":"2019050109251922000_46.5.509.34","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000104"},{"key":"2019050109251922000_46.5.509.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909530"},{"key":"2019050109251922000_46.5.509.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211400"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.180778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T13:10:25Z","timestamp":1556716225000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.180778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,15]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,1]]},"published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.3899\/jrheum.180778"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.180778","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,15]]}}}